Guggenheim Cuts Tempus AI (NASDAQ:TEM) Price Target to $60.00

Tempus AI (NASDAQ:TEM) had its price objective decreased by Guggenheim from $95.00 to $60.00 in a research note issued to investors on Monday,Benzinga reports. Guggenheim currently has a buy rating on the stock.

Other research analysts have also recently issued reports about the company. Canaccord Genuity Group cut their price objective on Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, December 22nd. JPMorgan Chase & Co. lowered their target price on shares of Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Morgan Stanley dropped their target price on shares of Tempus AI from $85.00 to $70.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. HC Wainwright lifted their price target on shares of Tempus AI from $89.00 to $95.00 and gave the company a “buy” rating in a report on Monday, March 9th. Finally, BTIG Research decreased their price objective on shares of Tempus AI from $105.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $75.92.

Tempus AI Price Performance

Shares of TEM stock opened at $47.03 on Monday. The stock’s fifty day simple moving average is $53.75 and its 200 day simple moving average is $68.82. Tempus AI has a one year low of $36.22 and a one year high of $104.32. The firm has a market cap of $8.41 billion, a price-to-earnings ratio of -33.35 and a beta of 4.87. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00.

Insider Buying and Selling

In related news, EVP Erik Phelps sold 9,464 shares of Tempus AI stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.43, for a total value of $562,445.52. Following the completion of the transaction, the executive vice president directly owned 79,816 shares of the company’s stock, valued at $4,743,464.88. The trade was a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Andrew Polovin sold 10,949 shares of the company’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $60.31, for a total transaction of $660,334.19. Following the transaction, the executive vice president owned 126,918 shares in the company, valued at approximately $7,654,424.58. This trade represents a 7.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 568,841 shares of company stock valued at $32,579,611. Insiders own 26.27% of the company’s stock.

Institutional Investors Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TEM. Vanguard Group Inc. lifted its position in shares of Tempus AI by 8.7% during the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock worth $605,772,000 after purchasing an additional 817,014 shares in the last quarter. ARK Investment Management LLC increased its holdings in shares of Tempus AI by 5.3% in the fourth quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock valued at $446,275,000 after purchasing an additional 381,816 shares in the last quarter. GC Wealth Management RIA LLC bought a new position in Tempus AI in the 4th quarter worth approximately $399,267,000. Sumitomo Mitsui Trust Group Inc. raised its position in Tempus AI by 1.2% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,504,823 shares of the company’s stock worth $206,960,000 after purchasing an additional 41,728 shares during the last quarter. Finally, Amova Asset Management Americas Inc. lifted its holdings in Tempus AI by 1.2% during the 4th quarter. Amova Asset Management Americas Inc. now owns 3,504,823 shares of the company’s stock worth $206,960,000 after buying an additional 41,728 shares in the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: ALERT trial with Medtronic shows Tempus’ AI-driven EHR alerts improved timely evaluation and treatment for aortic stenosis and mitral regurgitation across multiple health systems — evidence the company can convert real-world data/AI into measurable care improvements that support commercial adoption. Tempus and Medtronic Announce ALERT Trial Results Showing AI-Driven EHR Notifications Improve Treatment for Significant Valvular Heart Disease
• Positive Sentiment: Diagnostics segment set for strong 2026 growth driven by oncology test demand, expanding minimal residual disease (MRD) adoption, higher pricing and improving reimbursement — a near-term revenue and margin tailwind for Tempus’ core business. What’s Fueling TEM Diagnostics Segment’s Strong 2026 Outlook?
• Positive Sentiment: Collaboration with Daiichi Sankyo targets precision oncology drug development (antibody drug conjugate program) using Tempus’ multimodal AI and RWD — validates Tempus’ platform to support large pharma trials and could accelerate commercial partnerships and revenue through sponsor-led programs. Tempus AI Daiichi Sankyo Tie Up Highlights Precision Oncology Opportunity
• Positive Sentiment: Bullish investor write-ups highlight Tempus’ massive data asset (cited ~450 petabytes) and AI models as a durable moat with upside from model monetization and diagnostics growth — supports valuation narratives for long-term growth investors. Tempus AI: 450-Petabyte Moat, High-Growth Upside At A Discount
• Neutral Sentiment: High-profile media commentary is mixed: Jim Cramer called TEM “a decent spec” and suggested holding some shares rather than all — useful for retail sentiment but not a fundamental change. Jim Cramer on Tempus AI: “It’s a Decent Spec, I Would Hold on to Some, But Not All”
• Neutral Sentiment: Comparisons and analyst pieces (TEM vs. peers like DOCS/SDGR) highlight both upside from AI/RWD and the question of sustainable monetization — useful framing for relative valuation and competitive risk. TEM vs. DOCS: Which Medical Info Systems Stock Is the Better Pick Now?
• Negative Sentiment: Risk factors that could cap the stock: negative GAAP profitability (negative P/E), high debt-to-equity (2.52), elevated beta (~5.3) and the share price sitting below the 50- and 200-day moving averages — signals of execution/volatility risk that can amplify sell-offs if growth/reimbursement or partnership milestones slip.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.